Inhibikase TherapeuticsInc Company Insiders
| IKT Stock | USD 1.89 0.03 1.61% |
Inhibikase TherapeuticsInc employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive. Breaking down Inhibikase TherapeuticsInc's management performance can provide insight into the firm performance.
Inhibikase |
Inhibikase TherapeuticsInc Management Team Effectiveness
The company has Return on Asset of (0.6423) % which means that on every $100 spent on assets, it lost $0.6423. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.1964) %, meaning that it generated no profit with money invested by stockholders. Inhibikase TherapeuticsInc's management efficiency ratios could be used to measure how well Inhibikase TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2024. Return On Capital Employed is likely to gain to -1.72 in 2024. At this time, Inhibikase TherapeuticsInc's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 85.6 K in 2024.Common Stock Shares Outstanding is likely to drop to about 3.2 M in 2024. Net Loss is likely to gain to about (12.6 M) in 2024
Inhibikase TherapeuticsInc Workforce Comparison
Inhibikase TherapeuticsInc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 154. Inhibikase TherapeuticsInc holds roughly 8.0 in number of employees claiming about 5% of equities under Health Care industry.
Inhibikase TherapeuticsInc Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Inhibikase TherapeuticsInc insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Milton Werner over a month ago Acquisition by Milton Werner of 45000 shares of Inhibikase TherapeuticsInc at 2.16 subject to Rule 16b-3 | ||
Berman Dennis N over a month ago Acquisition by Berman Dennis N of 22677 shares of Inhibikase TherapeuticsInc at 2.92 subject to Rule 16b-3 | ||
Milton Werner over a month ago Acquisition by Milton Werner of 210000 shares of Inhibikase TherapeuticsInc at 0.74 subject to Rule 16b-3 | ||
Lees-rolfe Garth over a month ago Disposition of 5834 shares by Lees-rolfe Garth of Inhibikase TherapeuticsInc at 3.79 subject to Rule 16b-3 | ||
Berman Dennis N over six months ago Acquisition by Berman Dennis N of 6667 shares of Inhibikase TherapeuticsInc subject to Rule 16b-3 | ||
Frattaroli Joseph over a year ago Inhibikase TherapeuticsInc exotic insider transaction detected |
Inhibikase TherapeuticsInc Notable Stakeholders
An Inhibikase TherapeuticsInc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inhibikase TherapeuticsInc often face trade-offs trying to please all of them. Inhibikase TherapeuticsInc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inhibikase TherapeuticsInc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Milton Werner | President CEO | Profile | |
| Roger Rush | Head Research | Profile | |
| BSc FRCPC | Interim Advisor | Profile | |
| Garth LeesRolfe | Chief Officer | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Surendra Singh | Manufacturing Chemistry | Profile | |
| Dan Williams | Controller | Profile |
About Inhibikase TherapeuticsInc Management Performance
The success or failure of an entity such as Inhibikase TherapeuticsInc often depends on how effective the management is. Inhibikase TherapeuticsInc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inhibikase management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inhibikase management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (1.82) | (1.72) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | (1.73) | (1.65) |
The data published in Inhibikase TherapeuticsInc's official financial statements usually reflect Inhibikase TherapeuticsInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inhibikase TherapeuticsInc. For example, before you start analyzing numbers published by Inhibikase accountants, it's critical to develop an understanding of what Inhibikase TherapeuticsInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Inhibikase TherapeuticsInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inhibikase TherapeuticsInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inhibikase TherapeuticsInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibikase TherapeuticsInc. Please utilize our Beneish M Score to check the likelihood of Inhibikase TherapeuticsInc's management manipulating its earnings.
Inhibikase TherapeuticsInc Workforce Analysis
Traditionally, organizations such as Inhibikase TherapeuticsInc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inhibikase TherapeuticsInc within its industry.Inhibikase TherapeuticsInc Manpower Efficiency
Return on Inhibikase TherapeuticsInc Manpower
| Revenue Per Employee | 32.6K | |
| Revenue Per Executive | 37.2K | |
| Net Loss Per Employee | 2.4M | |
| Net Loss Per Executive | 2.7M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 1.5M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Inhibikase Stock analysis
When running Inhibikase TherapeuticsInc's price analysis, check to measure Inhibikase TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase TherapeuticsInc is operating at the current time. Most of Inhibikase TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Inhibikase TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase TherapeuticsInc's price. Additionally, you may evaluate how the addition of Inhibikase TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Inhibikase TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase TherapeuticsInc. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.32) | Revenue Per Share 0.034 | Quarterly Revenue Growth (1.00) | Return On Assets (0.64) | Return On Equity (1.20) |
The market value of Inhibikase TherapeuticsInc is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Inhibikase TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase TherapeuticsInc's market value can be influenced by many factors that don't directly affect Inhibikase TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.